Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC Filings

SEC Filings

Filing date	Form	Description	View
Jan 17, 2014	D		View HTML 0001597264-14-000001.pdf 0001597264-14-000001.rtf 0001597264-14-000001.xls
Nov 20, 2014	D		View HTML 0001597264-14-000002.pdf 0001597264-14-000002.rtf 0001597264-14-000002.xls
Feb 19, 2015	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	View HTML 0000912057-15-000045.pdf 0000912057-15-000045.rtf 0000912057-15-000045.xls
Mar 16, 2015	DRS/A	mendment to a previously filed DRS	View HTML 0000912057-15-000057.pdf 0000912057-15-000057.rtf 0000912057-15-000057.xls
Mar 20, 2015	UPLOAD	UPLOAD	View HTML 0000000000-15-016713.pdf
Mar 23, 2015	S-1	Registration statement for face-amount certificate companies	View HTML 0001047469-15-002608.pdf 0001047469-15-002608.rtf 0001047469-15-002608.xls
Mar 23, 2015	CORRESP	CORRESP	View HTML 0001104659-15-021789.pdf 0001104659-15-021789.rtf 0001104659-15-021789.xls
Apr 08, 2015	CORRESP	CORRESP	View HTML 0001104659-15-026544.pdf 0001104659-15-026544.rtf 0001104659-15-026544.xls
Apr 08, 2015	UPLOAD	UPLOAD	View HTML 0000000000-15-020307.pdf
Apr 10, 2015	S-1/A	Amended Registration statement for face-amount certificate companies	View HTML 0001047469-15-003351.pdf 0001047469-15-003351.rtf 0001047469-15-003351.xls

Continue